Head and Neck Cancer

PD 10 - H&N 2 - Head and Neck Poster Discussion

1087 - A Multi-Institutional Comparison of Carboplatin-Based Regimens Versus Cetuximab in Chemoradiation for p16(-) Head and Neck Cancer

Tuesday, October 23
1:36 PM - 1:42 PM
Location: Room 217 A/B

A Multi-Institutional Comparison of Carboplatin-Based Regimens Versus Cetuximab in Chemoradiation for p16(-) Head and Neck Cancer
C. Barney1, T. Beckham2, E. Healy1, A. Branstetter1, A. Yaney1, N. Riaz2, S. M. McBride2, C. J. Tsai2, E. Sherman3, L. Dunn3, D. G. Pfister3, J. Tan4, R. Rupert5, M. Bonomi5, D. L. Mitchell1, J. L. Wobb1, D. M. Blakaj1, N. Lee2, and A. D. Bhatt1; 1The Ohio State University Wexner Medical Center, Department of Radiation Oncology, Columbus, OH, 2Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, NY, 3Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, New York, NY, 4The Ohio State University Wexner Medical Center, Department of Biostatistics, Columbus, OH, 5The Ohio State University Wexner Medical Center, Division of Medical Oncology, Columbus, OH

Purpose/Objective(s): When patients cannot receive cisplatin (CP) with definitive radiation therapy (RT) for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC), concurrent cetuximab (C225) is an increasingly popular substitute. However, some studies have shown only marginal tumor control benefit with C225 in p16(-) HNSCC. Carboplatin-based (CB) chemoradiation (CRT) is another alternative to CP-CRT in this population. We hypothesized that CB-CRT would improve locoregional control (LRC) and recurrence-free survival (RFS) compared to C225-RT in cisplatin ineligible p16(-) LA-HNSCC.

Materials/Methods: From two institutions we identified 325 patients with treatment-naïve p16(-) LA-HNSCC (stages III-IVB) of the oropharynx (25.5%), larynx (57.5%), and hypopharynx (16.9%) who received definitive (median 70 Gy) C225-RT (n=65), CB-CRT (n=79; singlet=27, doublet=52), or CP-CRT (n=181) from 2002-2015. Outcomes were estimated with Kaplan-Meier analysis and Cox regression was used to determine the impact of gender, age, smoking, T-stage, N-stage, performance status, comorbidity index, and primary tumor site. Covariates with p<.10 were included in multivariate analysis (MVA) to adjust for confounders.

Results: Median age was 61 yrs; ≥T3 (63.7%), ≥N2b (50.2%); median follow up was 51 months. Patient characteristics were balanced between CB-CRT and C225-RT patients; CP-CRT patients were younger (p<.001) and had less comorbidities (p<.001). Respectively, 3-yr outcomes for CP-CRT, CB-CRT, and C225-RT were: LRC (78.0, 81.2, and 49.4%), distant metastasis-free survival (DMFS; 81.4, 84.4, and 71.7%), RFS (67.9, 72.0, and 44.5%), and overall survival (OS; 71.1, 61.0, and 55.1%). On MVA, CB-CRT was associated with improved LRC, RFS, and DMFS, with a trend toward a reduced risk of mortality when compared to C225-RT [table]. Conversely, similar rates of LRC, DMFS, RFS, and OS were noted with CB-CRT and CP-CRT on MVA [table].

LRC

DMFS

RFS

OS

Adjusted HR (95%CI)

p

Adjusted HR (95%CI)

p

Adjusted HR (95%CI)

P

Adjusted HR (95%CI)

p

CB vs CP

0.72

(0.37, 1.39)

0.33

0.66

(0.33, 1.30)

0.23

0.73

(0.43, 1.23)

.24

1.05

(0.69, 1.59)

.84

C225-RT vs CP

2.44

(1.46, 4.08)

<.001

1.44

(0.78, 2.66)

0.25

1.86

(1.19, 2.89)

.006

1.51

(0.99, 2.32)

.06

C225-RT vs CB

3.39

(1.69, 6.76)

<.001

2.19

(0.99, 4.81)

0.05

2.55

(1.44, 4.52)

.001

1.45

(0.90, 2.34)

.13

Conclusion: When patients cannot receive cisplatin, carboplatin-based CRT is an effective alternative in p16(-) LA-HNSCC. Furthermore, CB-CRT was associated with improved LRC, DMFS, and RFS compared to C225-RT and seems to be a preferred alternative in this population. Prospective validation of these results is needed.

Author Disclosure: C. Barney: None. T. Beckham: None. E. Healy: None. A. Branstetter: None. N. Riaz: None. S.M. McBride: None. D.G. Pfister: Research Grant; AstraZeneca, Medimmune, Merck, Novartis, Pfizer, Regeneron. Consultant; Boehringer-Ingelheim. Chair, HN Committee; Member, Board of Directors/Ex; National Comprehensive Cancer Network. D.L. Mitchell: None. D.M. Blakaj: None. N. Lee: Consultant; Lily. Advisory Board; Pfizer, Vertex, Merck.

Christian Barney, MD, BS

Disclosure:
Employment
Ohio State University Medical Center: Radiation Oncology Resident: Employee

Presentation(s):

Send Email for Christian Barney


Assets

1087 - A Multi-Institutional Comparison of Carboplatin-Based Regimens Versus Cetuximab in Chemoradiation for p16(-) Head and Neck Cancer



Attendees who have favorited this

  • C Jillian Tsai
    Assistant Attending
    Memorial Sloan Kettering Cancer Center

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for A Multi-Institutional Comparison of Carboplatin-Based Regimens Versus Cetuximab in Chemoradiation for p16(-) Head and Neck Cancer